Prestige Consumer Healthcare Inc. markets, sells, manufactures and distributes over-the-counter consumer healthcare products to retail outlets in the U.S. and Canada, Australia and other international markets. Its brand portfolio spans women’s health, pain relief, eye care, oral care, motion sickness, gastrointestinal, pediatric, lice treatment, ear care, rehydration, and nasal and sinus care, including Monistat, Summer’s Eve, Clear Eyes, TheraTears, DenTek, Dramamine, Fleet, Chloraseptic, Compound W, Little Remedies, Nix, Debrox, Hydralyte and Fess.
Company news commonly covers fiscal earnings releases, investor presentations, brand and category performance, supply conditions for key products such as Clear Eyes, share repurchase activity, capital-structure updates, material agreements and completed portfolio actions such as the Pillar5 Pharma eye care supplier acquisition.
Prestige Consumer Healthcare (PBH) shared Summer's Eve survey findings showing persistent discomfort among U.S. women when discussing intimate health and wellness. The OnePoll survey of 2,000 U.S. women found that 63% believe women are more comfortable discussing these subjects than five years ago, yet 52% have avoided a conversation because of embarrassment or discomfort. Only 18% believe vaginal/vulvar health and wellness is discussed openly and comfortably in society today.
Among respondents, 57% use euphemisms or coded language at least sometimes, and 56% say humor makes these conversations more comfortable. Avoiding a conversation was reported by 61% of Gen Z respondents, compared with 46% of Boomers. The findings support Summer's Eve's “Let's Talk About It” initiative, which combines humor and candid conversation. The brand also joined BeaverCON, a beaver conservation conference, and is sharing additional research findings on its website.
Prestige Consumer Healthcare (PBH)/b) will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026, at 12:45 p.m. ET.A live webcast will be accessible via the company’s website under the Investors section and the Events and Presentations tab, or through the provided events link. A replay of the webcast will be available on the company’s website for those unable to listen live.
Prestige Consumer Healthcare (NYSE: PBH), through its DenTek oral care brand, released findings from the inaugural Football Stress Test, a national survey of 1,000 U.S. football fans. According to DenTek, 78% of fans keep thinking about football after games and 77% do so after getting into bed, with 47% staying up later than planned.
The survey links stressful football experiences with stress-related behaviors at night: among fans who find the season stressful, 39% feel anxious, 32% have trouble falling asleep, 21% report jaw tension or clenching, and 69% say they grind or clench their teeth at least sometimes during stressful games. DenTek is using these insights in its Fantasy Guards 2.0 campaign with NFL legends Ronde and Tiki Barber to highlight connections between football stress, nighttime teeth grinding and demand for DenTek Nighttime Dental Guards, sold at major U.S. retailers.
Prestige Consumer Healthcare (NYSE:PBH) announced that CFO and COO Christine Sacco and VP Investor Relations, Treasury & Business Development Phil Terpolilli will join a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026 at 10:00 a.m. ET. A live webcast and replay will be accessible via the company’s investor relations website.
Prestige Consumer Healthcare (NYSE:PBH) reported fiscal 2027 Q1 revenue of $265.7 million, up 6.5% year over year, with organic sales growth of 3.2%. Diluted EPS was $0.61 versus $0.95 a year ago, while adjusted diluted EPS rose to $0.98 from $0.95. Net income was $29.2 million, down from $47.5 million. Adjusted non-GAAP free cash flow increased to $83.7 million from $78.2 million, though operating cash flow declined to $70.8 million from $79.0 million.
According to Prestige Consumer Healthcare, Q1 results included about $6 million of revenue from the late-quarter Breathe Right acquisition. The company also closed the LaCorium Health acquisition in July and raised its fiscal 2027 outlook, now expecting revenue of $1.29–$1.315 billion, adjusted diluted EPS of $4.55–$4.65, and adjusted free cash flow of at least $270 million. Net debt was about $2.0 billion, and PBH refinanced $400 million of notes with new 6.25% senior notes due 2034.
Prestige Consumer Healthcare (NYSE:PBH) closed its approximately $150 million cash acquisition of LaCorium Health on July 1, 2026, funded with cash and existing credit facilities.
Prestige also priced $400 million 6.25% senior notes due 2034 to redeem its $400 million 5.125% notes due 2028, and will report fiscal 2027 Q1 earnings on August 6, 2026 with a conference call at 8:30 a.m. ET.
LaCorium generates about $40 million revenue and is expected to deliver roughly $12 million EBITDA including anticipated synergies when fully integrated.
Prestige Consumer Healthcare (NYSE: PBH) plans a private offering of up to $400 million senior unsecured notes due 2034 through subsidiary Prestige Brands.
According to Prestige Consumer Healthcare, net proceeds and cash on hand are intended to redeem all $400 million 5.125% senior notes due 2028 and pay related fees.
Prestige Consumer Healthcare (NYSE:PBH) completed its acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare on June 15, 2026.
The deal is valued at $1.045 billion, or about $900 million net after anticipated $150 million tax benefits, and makes Breathe Right Prestige’s largest brand, adding a new product category.
Prestige Consumer Healthcare (NYSE:PBH) will join the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference via a virtual fireside chat on Monday, June 8, 2026 at 9:45 a.m. ET.
A live webcast and replay will be available on the company’s investor relations website.
Prestige Consumer Healthcare (NYSE:PBH) reported fiscal 2026 revenue of $1,088.7 million and Q4 revenue of $281.6 million, both down year over year. Fiscal 2026 diluted EPS was $3.91, with adjusted diluted EPS of $4.38. Free cash flow rose to $246.4 million, and operating cash flow reached $257.6 million. The company repurchased 2.3 million shares for about $156 million.
Prestige agreed to acquire LaCorium Health for approximately $150 million in cash; LaCorium generated about $40 million in trailing-12-month revenue. Fiscal 2027 guidance targets revenue of $1.10–$1.121 billion, organic growth of 1–3%, adjusted EPS of $4.42–$4.51, and free cash flow of $250+ million.